Bleomycin pharmacokinetics

Alberts DS, Chen HS, Mayersohn M, Perrier D, Moon TE, Gross JF. Bleomycin pharmacokinetics in man. II. Intracavitary administration. Cancer Chemother Pharmacol 1979 2(2) 127-32. 

Pharmacokinetics Bleomycin must be given parenterally. It is inactivated by tissue aminopeptidases, but some renal clearance of intact drug also occurs. 

The antibiotics are drugs isolated from the fungal species Streptomyces. They are classified together based solely on their origin. These agents have different mechanisms of action, toxicides, pharmacokinetics and clinical indications. Therefore, it is not useful to simply learn a prototype drug for this class. The most commonly used antibiotics are adriamycin, actinomycin D, mitomycin C and bleomycin. 

Some evidence su ests ondansetron may modestly affect the pharmacokinetics of cyclophosphamide and cisplatin but it does not appear to affect those of carmustine. Ondansetron did not affect the in vitro activity of epirubicin, bleomycin, cisplatin or es-tramustine. Cisplatin and fluorouracil do not affect the pharmacokinetics of ondansetron. In in vitro studies granisetron potentiated the cytotoxic effects of epirubicin, had an additive effect on bleomycin and estramustine activity and appeared not to affect the metabolism of docetaxel and paclitaxel. 

---